Key result
Heart failure with mid-range ejection fraction represents an intermediate clinical phenotype between reduced and preserved ejection fraction, with distinct characteristics and mortality outcomes.
Answers are grounded in this paper and cite their sources.
This editorial highlights that HFmrEF represents a distinct clinical entity with intermediate characteristics between HFrEF and HFpEF, and advocates for the continued use of guideline-directed medical therapies like beta-blockers in these patients.
HFmrEF have been extensively published since then. In the beginning, most reports HFmrEF were from European countries and North America. More recently, reports from Asian countries, including Cho et al's paper in this issue of the Journal, 2-8 followed, some of them investigating I n 2016, the ESC guidelines 1 categorized heart (HF) into 3 classes according to LVEF: HFrEF, HFmrEF and HFpEF (HF with reduced, mid-range and preserved ejection fraction (EF), respectively). However, HFmrEF, a newly provided category of HF, is quite expedient for filling the blank zone or a buffer zone between HFrEF and HFpEF. Nevertheless, the ESC 2016 classification was generally accepted and clinical reports on
No takes yet. Share an insight, caveat, or question.
Momomura et al. (2018) conducted an editorial in Heart failure with mid-range ejection fraction (HFmrEF). Heart failure with mid-range ejection fraction (HFmrEF) vs. Heart failure with reduced (HFrEF) or preserved (HFpEF) ejection fraction was evaluated. Heart failure with mid-range ejection fraction represents an intermediate clinical phenotype between reduced and preserved ejection fraction, with distinct characteristics and mortality outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: